论文部分内容阅读
目的:观察复方益肝灵胶囊预防抗结核药物所致肝损伤的临床效果。方法:选取肺结核患者96例,随机分为对照组和观察组各48例。对照组患者给予常规抗结核药物并口服葡醛内酯片治疗;观察组患者在常规抗结核治疗的基础上给予复方益肝灵胶囊联合治疗,治疗6月。观察治疗过程中患者临床症状、体征和肝功能的变化情况及抗结核治疗的中断情况。结果:临床不适发生率观察组为18.75%,对照组为52.08%,2组比较,差异有显著性意义(P<0.05)。治疗结束,2组谷丙转氨酶(ALT)、谷草转氨酶(AST)和总胆红素(TBil)分别与治疗前比较,差异均有显著性意义(P<0.05)。治疗1月和治疗结束,2组ALT比较,差异均有显著性意义(P<0.05)。药物性肝损伤发生率观察组为14.58%,对照组为25.00%,2组比较,差异有显著性意义(P<0.05)。结论:复方益肝灵胶囊能保护肝脏,提高肝脏功能,对抗结核药物所致的肝损伤具有良好的预防作用。
Objective: To observe the clinical effect of compound Yiganling capsule in preventing hepatic injury induced by antituberculosis drugs. Methods: Ninety-six patients with pulmonary tuberculosis were randomly divided into control group and observation group of 48 cases. Patients in the control group were given conventional antituberculotics and oral glucurolactone tablets. Patients in the observation group were treated with Fufang Yigan Capsules on the basis of routine antituberculous therapy for 6 months. Observed during treatment of patients with clinical symptoms, signs and changes in liver function and the interruption of anti-TB treatment. Results: The incidence of clinical disability was 18.75% in the observation group and 52.08% in the control group. There was significant difference between the two groups (P <0.05). At the end of treatment, the differences of ALT, AST and TBil between the two groups were statistically significant (P <0.05). After treatment for 1 month and treatment ended, there was significant difference between two groups (P <0.05). The incidence of drug-induced liver injury was 14.58% in the observation group and 25.00% in the control group. There was significant difference between the two groups (P <0.05). Conclusion: Yiganling Capsule can protect the liver, improve liver function and prevent liver injury caused by tuberculosis drugs.